Welcome to the new Gustave Roussy website
A new website designed to offer you a simpler, clearer, and more intuitive experience. Patients, caregivers, healthcare professionals, and donors: find information, news, and services more easily.
Gustave Roussy and Takeda announce scientific partnership to advance innovative research programs in solid tumors and hematologic malignancies
Paris, 5 November 2026 – Gustave Roussy, the leading cancer center in both France and Europe and ranked third worldwide, and Takeda have announced a new scientific partnership. This long-term collaboration will support oncology research projects from laboratory studies through the various stages of clinical development.
On
The partnership brings together the complementary strengths of both organizations. Gustave Roussy will draw on its multidisciplinary teams, scientific platforms and extensive clinical research experience, while Takeda will make its innovation programs and expertise in clinical and pharmaceutical development available. The partnership will focus initially on the areas of thoracic and gastrointestinal cancers and will foster close collaboration among researchers, clinicians and development teams.
Research will seek to deepen understanding of the biological and clinical mechanisms of certain Takeda investigational medicines, identify relevant biomarkers and better define the patient populations most likely to benefit from the approaches under investigation. They will span several stages of research, from clinical and preclinical studies to translational analyses.
“Our mission is to turn advances in research into knowledge that benefits patients. By bringing together our teams, platforms and clinical research experience with Takeda’s programs, we remain committed to Gustave Roussy’s ambition: to ensure that every patient can benefit from the very best advances in cancer care,” adds Professor Fabrice Barlesi, Chief Executive Officer of Gustave Roussy.
“This partnership reflects Takeda's belief that accelerating progress in oncology is enabled by bringing together complementary expertise and capabilities. By combining Gustave Roussy's scientific expertise, translational platforms and clinical capabilities with Takeda's innovative programs, we aim to generate meaningful insights more quickly and advance new treatment options for patients living with cancer,” said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit at Takeda.
Press contact
If you are a journalist and have a question, please contact:
Claire Parisel or Léona Pinto
Tel. +33 1 42 11 50 59
Tel. +33 1 42 11 63 59
Mob. +33 6 17 66 00 26
Email
The Media Team cannot respond to patient inquiries.
Last press releases
-
ESMO 2026 - Addressing the side effects of endocrine therapy: a new care pathway combining digital support and human expertise
Dr Maria Alice Franzoi, medical oncologist and specialist in digital health and care pathway implementation, will present the results of the HOPE study at the ESMO Congress. This clinical trial evaluated a hybrid care pathway combining a mobile application and nurse-led support to help women receiving endocrine therapy for breast cancer. The aim is to reduce the burden of treatment-related side effects, which can compromise adherence to a therapy that is essential for lowering the risk of recurrence, while strengthening patients’ confidence in managing their symptoms. Ultimately, this approach seeks to improve quality of life, access to supportive care, and long-term continuation of endocrine therapy.
-
ESMO 2026 - Exploring the potential of immunotherapy in early-stage triple-negative breast cancer
Dr Joana Ribeiro, medical oncologist in the Drug Development Department at Gustave Roussy, will present the results of the POP-DURVA clinical trial at the ESMO Congress. Conducted within UNLOCK, a flagship programme of the PRISM Institute, the study evaluated the addition of two immunotherapy injections before surgery in women with localised triple-negative breast cancer. With a strong translational research component, the study also investigated immunotherapy's early effects on the tumour and its immune microenvironment, to better understand the mechanisms underlying treatment response.
-
INTERCEPTION: The national pilot program for personalized cancer prevention among individuals at increased risk of cancer enters its operational phase with the enrollment of the first patients
The Interception program has reached a new milestone with the enrollment of its first patients as part of the national Article 51 pilot program. Rolled out over four years across seven healthcare facilities, this pilot program is designed to evaluate an innovative model for personalized cancer prevention and screening.
-
After a breast cancer diagnosis, how can treatment be started more quickly?
Gustave Roussy is launching a new care pathway designed to accelerate the management of women recently diagnosed with breast cancer. It brings together, in a single day, the radiology examinations, blood tests, and oncology consultation required to initiate treatment. This new pathway complements the Institute’s rapid breast care offering. The InstaDiag Breast pathway already consolidates all diagnostic examinations into a single day to establish a diagnosis.
